The State-owned Assets Supervision and Administration Commission and the National Development and Reform Commission jointly issued significant venture capital policies, and the equity market is expected to enter a period of development and prosperity.

① The State-owned Assets Supervision and Administration Commission (SASAC) and the National Development and Reform Commission jointly issued policy measures to promote the high-quality development of venture capital funds by central enterprises, supporting these enterprises to initiate and establish venture capital funds, focusing on early-stage, small-scale, long-term investments, and hard technology. ② Citic sec research reports indicate that in the context of the secondary market entering a valuation expansion cycle, with the increasing linkage effect between the primary and secondary markets, the equity market will also move towards a prosperous period of high-quality development.

cls.cnDec 2 19:02 ET

Jinyu bio-technology: The industry is in the lowest point in history. New products next year will contribute to revenue growth | Direct coverage of the earnings conference.

① At the performance briefing, the chairman of jinyu bio-technology, Zhang Chongyu, admitted that the industry is currently at its lowest point in history; ② The company stated that competition in the pig vaccine market is fierce, and it will maintain its existing market share. Several new vaccines will be launched in the next two years, and it is expected that the new products will contribute a certain revenue increment next year.

cls.cnNov 28 05:50 ET

Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference

① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.

cls.cnNov 27 09:29 ET

Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.

① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.

cls.cnNov 22 11:06 ET

No money again! Shenzhen Chipscreen Biosciences has "burned" 0.9 billion in R&D expenses over three years and plans to raise another 0.96 billion, nearly 30% of which will be used to supplement cash flow.

shenzhen chipscreen biosciences announced a plan for private placement, planning to raise 0.96 billion yuan, with 0.71 billion yuan for innovative drug research and development, and 0.25 billion yuan for supplementary working capital, reaching a replenishment ratio of 26.04%; Multiple research pipelines continue to burn money for shenzhen chipscreen biosciences, with a total research and development expense of 0.927 billion yuan from 2021 to 2023, currently 17 indication pipelines are in clinical trial stage.

cls.cnNov 21 04:55 ET

Star Evening News | kbc corporation,ltd. affiliated companies' silicon-based anode series products have formed bulk supply. shenzhen chipscreen biosciences plans to raise no more than 0.96 billion yuan through a private placement.

1. Polymax Materials' shareholder plans to reduce its shareholding by no more than 3% of the company's shares; 2. Micronano intends to repurchase shares ranging from 40 million yuan to 80 million yuan; 3. Beijing Hotgen Biotech Co.,Ltd. plans to repurchase shares at a range of 58 million yuan to -0.1 billion yuan; 4. Suzhou Hyc Technology plans to repurchase shares at a range of 25 million yuan to -50 million yuan.

cls.cnNov 20 07:56 ET